Good News for Nymox's Pipeline - Analyst Blog
March 21 2013 - 2:25PM
Zacks
Positive news flowed in at Nymox Pharmaceutical
Corporation (NYMX) recently when the Independent Data
Monitoring Committee (IDMC) reported the third positive analysis of
safety data from the company’s ongoing phase II study (NX03-0040)
of NX-1207 for low grade localized prostate cancer.
The IDMC’s interim safety analysis found no significant safety
concerns associated with the use of NX-1207 for the treatment of
low risk localized prostate cancer. The NX03-0040 study is
assessing the efficacy and safety of both low (2.5 mg) and high (15
mg) single doses of NX-1207 in eradicating or shrinking low grade
localized prostate cancer tumors. The phase II study is ongoing and
is expected to be completed by May 2013.
NX-1207 is in phase III development both in the US and Europe for
the treatment of patients suffering from benign prostatic
hyperplasia (BPH). In Europe, the company has a licensing agreement
with Recordati S.p.A. Recordati is sponsoring the recently
initiated phase III study in Europe.
We note that the prostrate cancer market offers a lucrative
opportunity. Currently approved prostate cancer treatments include
Johnson & Johnson’s (JNJ) Zytiga. Moreover,
the prostate cancer market saw a new entrant in Aug 2012 in the
form of Medivation’s (MDVN) Xtandi
(enzalutamide).
Nymox Pharma currently carries a Zacks Rank #3 (Hold). Stocks that
currently look attractive in the pharma space include companies
like Cytokinetics, Inc. (CYTK) carrying a Zacks
Rank #1 (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDIVATION INC (MDVN): Free Stock Analysis Report
NYMOX PHARMACTL (NYMX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024